Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.
BACKGROUND:The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. METHODS:We analyzed data from the National Health Insurance Research Database (NHIRD), a go...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4482692?pdf=render |
id |
doaj-c04b0248d02b4b97bfea184435cb175e |
---|---|
record_format |
Article |
spelling |
doaj-c04b0248d02b4b97bfea184435cb175e2020-11-25T02:40:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e013112210.1371/journal.pone.0131122Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan.Szu-Heng WangDong-Yi ChenYu-Sheng LinChun-Tai MaoMing-Lung TsaiMing-Jer HsiehChung-Chuan ChouMing-Shien WenChun-Chieh WangI-Chang HsiehKuo-Chun HungTien-Hsing ChenBACKGROUND:The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. METHODS:We analyzed data from the National Health Insurance Research Database (NHIRD), a government-operated, population-based database, from March 1st, 2009 to December 31st, 2011. Type 2 diabetic patients hospitalized for AMI were included in our study. We compared subjects using sitagliptin with comparison group to evaluate its cardiovascular safety and efficacy. The primary endpoint was a composite of cardiovascular death, myocardial infarction, and ischemic stroke. RESULTS:We identified a total of 3,282 type 2 diabetic patients hospitalized for AMI (mean follow-up 1.15 years). Of these patients, 547 (16.7%) who were exposed to sitagliptin were defined as the sitagliptin group and 2,735 (83.3 %) who did not use sitagliptin were the comparison group. The incidence of primary composite cardiovascular outcomes was 9.50 per 100 person-years in the sitagliptin group and was 9.70 per 100 person-years in the comparison group (hazard ratio (HR), 0.97; 95% CI, 0.73-1.29, P=0.849). Compared to the non-sitagliptin group, the sitagliptin group had similar risks of all-cause mortality, hospitalization for heart failure (HF) or percutaneous coronary intervention (PCI) with a HR of 0.82 (95% CI, 0.61-1.11, P=0.195), 0.93 (95% CI, 0.67-1.29, P=0.660), and 0.93 (95% CI, 0.75-1.14, P=0.473), respectively. CONCLUSION:The use of sitagliptin in type 2 diabetic patients with recent AMI was not associated with increased risk of adverse cardiovascular events.http://europepmc.org/articles/PMC4482692?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Szu-Heng Wang Dong-Yi Chen Yu-Sheng Lin Chun-Tai Mao Ming-Lung Tsai Ming-Jer Hsieh Chung-Chuan Chou Ming-Shien Wen Chun-Chieh Wang I-Chang Hsieh Kuo-Chun Hung Tien-Hsing Chen |
spellingShingle |
Szu-Heng Wang Dong-Yi Chen Yu-Sheng Lin Chun-Tai Mao Ming-Lung Tsai Ming-Jer Hsieh Chung-Chuan Chou Ming-Shien Wen Chun-Chieh Wang I-Chang Hsieh Kuo-Chun Hung Tien-Hsing Chen Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. PLoS ONE |
author_facet |
Szu-Heng Wang Dong-Yi Chen Yu-Sheng Lin Chun-Tai Mao Ming-Lung Tsai Ming-Jer Hsieh Chung-Chuan Chou Ming-Shien Wen Chun-Chieh Wang I-Chang Hsieh Kuo-Chun Hung Tien-Hsing Chen |
author_sort |
Szu-Heng Wang |
title |
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. |
title_short |
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. |
title_full |
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. |
title_fullStr |
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. |
title_full_unstemmed |
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. |
title_sort |
cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in taiwan. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
BACKGROUND:The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. METHODS:We analyzed data from the National Health Insurance Research Database (NHIRD), a government-operated, population-based database, from March 1st, 2009 to December 31st, 2011. Type 2 diabetic patients hospitalized for AMI were included in our study. We compared subjects using sitagliptin with comparison group to evaluate its cardiovascular safety and efficacy. The primary endpoint was a composite of cardiovascular death, myocardial infarction, and ischemic stroke. RESULTS:We identified a total of 3,282 type 2 diabetic patients hospitalized for AMI (mean follow-up 1.15 years). Of these patients, 547 (16.7%) who were exposed to sitagliptin were defined as the sitagliptin group and 2,735 (83.3 %) who did not use sitagliptin were the comparison group. The incidence of primary composite cardiovascular outcomes was 9.50 per 100 person-years in the sitagliptin group and was 9.70 per 100 person-years in the comparison group (hazard ratio (HR), 0.97; 95% CI, 0.73-1.29, P=0.849). Compared to the non-sitagliptin group, the sitagliptin group had similar risks of all-cause mortality, hospitalization for heart failure (HF) or percutaneous coronary intervention (PCI) with a HR of 0.82 (95% CI, 0.61-1.11, P=0.195), 0.93 (95% CI, 0.67-1.29, P=0.660), and 0.93 (95% CI, 0.75-1.14, P=0.473), respectively. CONCLUSION:The use of sitagliptin in type 2 diabetic patients with recent AMI was not associated with increased risk of adverse cardiovascular events. |
url |
http://europepmc.org/articles/PMC4482692?pdf=render |
work_keys_str_mv |
AT szuhengwang cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT dongyichen cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT yushenglin cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT chuntaimao cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT minglungtsai cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT mingjerhsieh cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT chungchuanchou cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT mingshienwen cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT chunchiehwang cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT ichanghsieh cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT kuochunhung cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan AT tienhsingchen cardiovascularoutcomesofsitagliptinintype2diabeticpatientswithacutemyocardialinfarctionapopulationbasedcohortstudyintaiwan |
_version_ |
1724782561478049792 |